公开(公告)号：WO2004040534A3

公开(公告)日：2004-08-05

申请号：PCT/US0333518

申请日：2003-10-23

Applicant: IDEXX LAB INC ,  MURTHY YERRAMILLI ,  SUVA ROBERT H

Inventor： MURTHY YERRAMILLI ,  SUVA ROBERT H

IPC: C07C45/45 ,  C07C49/788 ,  C07C49/813 ,  C07C49/84 ,  C07C49/92 ,  C07C51/44 ,  C07C225/22 ,  C07C255/56 ,  C07D213/50 ,  C07F9/53 ,  C07C49/115 ,  A61K31/74 ,  B01J10/00 ,  G01N33/543

CPC classification number: C07C49/84 ,  C07C45/455 ,  C07C49/788 ,  C07C49/813 ,  C07C49/92 ,  C07C51/44 ,  C07C225/22 ,  C07C255/56 ,  C07D213/50 ,  C07F9/5345 ,  C07C57/04

Abstract: beta-diketone fluorescent tags are disclosed, particularly those enabling the use of excitation energy in the near visible or visible spectrum. In some cases, these tags allow the use of cost-effective excitation devices such as LED's. The compounds form fluorescent chelates (complexes) with lanthanide (III) rare earth metal ions (such as EU3+). The fluorescent complex may be included in a latex microparticle, such as a styrene latex particle. Ideally, the complex has an absorption maximum lambda equal to or greater than 360 nm, and the compound is characterized by a pKa

Abstract translation: 公开了β-二酮荧光标签，特别是能够在近可见或可见光谱中使用激发能的那些标签。 在某些情况下，这些标签允许使用具有成本效益的激励装置，例如LED。 这些化合物与镧系元素（III）稀土金属离子（如EU3 +）形成荧光螯合物（配合物）。 荧光配合物可以包含在胶乳微粒中，例如苯乙烯胶乳颗粒。 理想情况下，该复合物具有等于或大于360nm的吸收最大λ，并且该化合物的特征在于pKa <9.0。 还公开了用于检测靶分子的试剂盒和方法（例如免疫分析）。 此类方法和试剂盒通常使用配体结合靶分子和附着于配体的标记试剂。 上述荧光复合物至少是标记试剂的一部分。 用于检测来自样品的荧光的装置包括产生等于或大于360nm的照射能量λ的照射能量源; 定位成检测来自样品的荧光的检测器; 以及用于将样品保持在能量源照射的位置的样品架。 照射能量源优选使用发光二极管。

公开(公告)号：EP1556323A4

公开(公告)日：2006-06-21

申请号：EP03779170

申请日：2003-10-23

Applicant: IDEXX LAB INC

Inventor： MURTHY YERRAMILLI ,  SUVA ROBERT H

IPC: C07C45/45 ,  C07C49/788 ,  C07C49/813 ,  C07C49/84 ,  C07C49/92 ,  C07C51/44 ,  C07C225/22 ,  C07C255/56 ,  C07D213/50 ,  C07F9/53 ,  C07C49/115 ,  A61K31/74 ,  B01J10/00 ,  G01N33/543

CPC classification number: C07C49/84 ,  C07C45/455 ,  C07C49/788 ,  C07C49/813 ,  C07C49/92 ,  C07C51/44 ,  C07C225/22 ,  C07C255/56 ,  C07D213/50 ,  C07F9/5345 ,  C07C57/04

Abstract: β-diketone fluorescent tags are disclosed, particularly those enabling the use of excitation energy in the near visible or visible spectrum. In some cases, these tags allow the use of cost-effective excitation devices such as LED’s. The compounds form fluorescent chelates (complexes) with lanthanide (III) rare earth metal ions (such as EU3+). The fluorescent complex may be included in a latex microparticle, such as a styrene latex particle. Ideally, the complex has an absorption maximum λ equal to or greater than 360 nm, and the compound is characterized by a pKa

公开(公告)号：EP1651202A4

公开(公告)日：2006-08-02

申请号：EP04777420

申请日：2004-06-29

Applicant: IDEXX LAB INC

Inventor： MURTHY YERRAMILLI ,  SUVA ROBERT H

IPC: A61K31/14 ,  A61K9/00 ,  A61K31/045 ,  A61K31/205 ,  A61K49/00 ,  A61P31/04 ,  C07C317/32

CPC classification number: A61K31/222 ,  A61K9/0019 ,  A61K9/0024 ,  A61K31/205 ,  A61K31/23 ,  A61K49/0004 ,  C07C317/32 ,  A61K2300/00

公开(公告)号：LT2313364T

公开(公告)日：2021-01-25

申请号：LT09790996

申请日：2009-07-30

Applicant: IDEXX LAB INC

Inventor： MURTHY YERRAMILLI ,  PADMANABHAN MAHALAKSHMI ,  ATKINSON MICHAEL ,  YEUNG KWOK

IPC: C07C279/12 ,  A61P13/12 ,  C07K16/44

公开(公告)号：ES2407812T3

公开(公告)日：2013-06-14

申请号：ES05766244

申请日：2005-06-23

Applicant: IDEXX LAB INC

Inventor： MURTHY YERRAMILLI

IPC: A61K47/24 ,  A61K9/00 ,  A61K9/06 ,  A61K9/127 ,  A61K31/137 ,  A61K31/573 ,  A61K31/7036 ,  A61K31/704

Abstract: Composición farmacéutica que comprende: (i) un fosfolípido; (ii) un disolvente orgánico aprótico polar; (iii) un disolvente orgánico prótico polar; (iv) hidroxipropilmetilcelulosa; y (v) un agente farmacéuticamente activo, estando la composición farmacéutica en forma de un gel.

公开(公告)号：HUE051130T2

公开(公告)日：2021-03-01

申请号：HUE09790996

申请日：2009-07-30

Applicant: IDEXX LAB INC

Inventor： MURTHY YERRAMILLI ,  PADMANABHAN MAHALAKSHMI ,  ATKINSON MICHAEL ,  YEUNG KWOK

IPC: A61P13/12 ,  C07K16/44

公开(公告)号：NZ531460A

公开(公告)日：2005-05-27

申请号：NZ53146002

申请日：2002-10-18

Applicant: IDEXX LAB INC

Inventor： MURTHY YERRAMILLI ,  SUVA ROBERT

IPC: A61K9/10 ,  A61K9/00 ,  A61K31/137 ,  A61K31/138 ,  A61K31/165 ,  A61K31/18 ,  A61K31/245 ,  A61K31/4704 ,  A61K31/496 ,  A61K31/505 ,  A61K31/65 ,  A61K31/7036 ,  A61K31/7048 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61K47/32 ,  A61K47/34 ,  A61P23/02 ,  A61P31/04

Abstract: Provided are compositions and methods for extending the release times and lowering the toxicity of pharmacologically active compounds. The compounds comprise a salt of the pharmacologically active compound with a lipophilic counterion and a pharmaceutically acceptable water soluble solvent combined together to form an injectable composition. The lipophilic counterion may be a saturated or unsaturated C8-C22 fatty acid, and preferably may be a saturated or unsaturated C10-C18 fatty acid. When injected into a non-human mammal, at least a portion of the composition precipitates and releases the active compound over time. Thus, the composition forms a slowly releasing drug depot of the active compound in the mammal. Therefore, controlled dose administration of the active compound is provided for a period of up to 15 days or longer. Many compounds can be administered including, but not limited to, tilmicosin, oxytetracycline, metoprolol, fluoxetine, roxithromycin, and turbinafine. Figure 3 is a graphical depiction illustrating that the rate of release of the pharmacologically active compound, tilmicosinm is affected by the chain length of the fatty acid selected. Solvent: N-methyl pyrrolidone; lipophilic counterion: decanoic acid and lauric acid.

公开(公告)号：AU2004258876B2

公开(公告)日：2009-02-26

申请号：AU2004258876

申请日：2004-06-29

Applicant: IDEXX LAB INC

Inventor： MURTHY YERRAMILLI ,  SUVA ROBERT H

IPC: A61K31/205 ,  A61K9/00 ,  A61K49/00 ,  C07C317/32

公开(公告)号：CA2580363A1

公开(公告)日：2006-05-11

申请号：CA2580363

申请日：2005-10-27

Applicant: IDEXX LAB INC

Inventor： MURTHY YERRAMILLI

IPC: A61K9/14 ,  A61F2/00 ,  A61K9/20 ,  A61K9/22 ,  A61K9/48 ,  C07B55/00 ,  C07C51/487 ,  C07D233/64

公开(公告)号：CA2542509A1

公开(公告)日：2005-05-19

申请号：CA2542509

申请日：2004-10-28

Applicant: IDEXX LAB INC

Inventor： MURTHY YERRAMILLI

IPC: A61K31/33 ,  A61K31/192 ,  A61K31/195 ,  A61K31/40 ,  A61K31/44 ,  A61K31/65 ,  A61K31/7048 ,  A61K31/7052 ,  A61K45/06

Abstract: The present invention relates to compositions containing at least two pharmacologically active ingredients. The compositions comprise a proton-donating pharmacologically active ingredient and a proton-accepting pharmacologically active ingredient in the form of a neutral salt. The salt can be dissolved in a solvent. Also provided are methods of administering pharmacologically active ingredients and methods of treating a disorder in an animal comprising administering to an animal in need thereof a salt of the invention.